Is early-onset primary Sjögren's syndrome a worse prognosis form of the disease?


Journal

Rheumatology (Oxford, England)
ISSN: 1462-0332
Titre abrégé: Rheumatology (Oxford)
Pays: England
ID NLM: 100883501

Informations de publication

Date de publication:
01 07 2019
Historique:
received: 31 05 2018
revised: 05 10 2018
pubmed: 19 12 2018
medline: 25 2 2020
entrez: 19 12 2018
Statut: ppublish

Résumé

Onset of primary SS is usually between 40 and 60 years of age, with severe systemic complications in 15% of cases. We sought to determine whether early-onset disease is related to a specific phenotype and if it is predictive of a poor outcome. Biological and clinical data from 393 patients recruited in the ASSESS cohort, a French multicentre prospective cohort, were compared according to age at diagnosis. Fifty-five patients had early-onset disease, defined as age ⩽35 years at diagnosis, and presented a significantly higher frequency of salivary gland enlargement (47.2% vs 33.3%, P = 0.045), adenopathy (25.5% vs 11.8%, P = 0.006), purpura (23.6% vs 9.2%, P = 0.002) and renal involvement (16.4% vs 4.4%, P = 0.003). They had a higher frequency of hypergammaglobulinaemia (60.8% vs 26.6%, P < 0.001), RF positivity (41.5% vs 20.2%, P < 0.001), low C3 level (18.9% vs 9.1%, P = 0.032), low C4 level (54.7% vs 40.2%, P = 0.048) and autoantibodies [84.6% with anti-SSA vs 54.4% (P < 0.001) and 57.7% with anti-SSB vs 29.7% (P < 0.001)]. The change in ESSDAI scores between baseline and the 5-year follow-up was significantly different (P = 0.005) with a trend for worsening in the early-onset group (0.72, P = 0.27) and a significant improvement in the later onset group (-1.27, P < 0.0001). Early-onset primary SS is associated with a specific phenotype defined by clinical and biological features known to be predictive factors of severe systemic disease. Interestingly, we showed a different evolution of the ESSDAI score depending on the age at disease onset, patients with early-onset disease tending to worsen over time.

Identifiants

pubmed: 30561748
pii: 5250863
doi: 10.1093/rheumatology/key392
doi:

Substances chimiques

Autoantibodies 0
Complement C3 0
Complement C4 0
Rheumatoid Factor 9009-79-4

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1163-1167

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

© The Author(s) 2018. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Auteurs

Céline Anquetil (C)

Service de médecine interne, CHU Claude Huriez, Lille Cedex, France.

Eric Hachulla (E)

Service de médecine interne, CHU Claude Huriez, Lille Cedex, France.

François Machuron (F)

Department of Biostatistics, Univ. Lille, CHU Lille, EA 2694 - Santé Publique : Épidémiologie et Qualité des Soins, Lille, France.

Xavier Mariette (X)

Service de rhumatologie, Hôpitaux Universitaires Paris-Sud, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris-Sud, Le Kremlin-Bicêtre, France.

Véronique Le Guern (V)

Centre de référence des maladies auto-immunes rares, CHU Cochin APHP, Paris, France.

Olivier Vittecoq (O)

Service de rhumatologie, CHU, Rouen, France.

Emmanuelle Dernis (E)

Service de rhumatologie, Centre hospitalier Le Mans, Le Mans Cedex, France.

Claire Larroche (C)

Service de médecine interne, Hôpital Avicenne APHP, Bobigny Cedex, France.

Jean-Jacques Dubost (JJ)

Service de rhumatologie, CHU Gabriel Montpied, Clermont-Ferrand Cedex, France.

Aleth Perdriger (A)

Service de rhumatologie, CHU, Rennes, France.

Valérie Devauchelle-Pensec (V)

Service de rhumatologie, CHU Cavale Blanche, INSERM 1227, Brest Cedex, France.

Anne-Laure Fauchais (AL)

Service de médecine interne, CHU, Limoges, France.

Jacques Morel (J)

Département de rhumatologie, CHU de Montpellier, Université de Montpellier, Montpellier, France.

Philippe Dieudé (P)

Service de rhumatologie, Hôpital Bichat AP-HP, Paris, France.

Stéphanie Rist (S)

Service de rhumatologie, CHU, Orléans, France.

Damien Sene (D)

Département de médecine interne, Hôpital Lariboisière APHP, Paris, France.

Jacques-Eric Gottenberg (JE)

Service de rhumatologie, CHU Hautepierre, Strasbourg, France.

Pierre-Yves Hatron (PY)

Service de médecine interne, CHU Claude Huriez, Lille Cedex, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH